Can Entresto (sacubitril/valsartan) and eplerenone cause acute kidney injury?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: November 20, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Can Entresto and Eplerenone Cause AKI?

Yes, both Entresto (sacubitril/valsartan) and eplerenone can cause acute kidney injury (AKI), and this risk requires mandatory serial monitoring of renal function during treatment with either medication.

Entresto (Sacubitril/Valsartan) and AKI Risk

FDA-Labeled Renal Safety Concerns

Entresto carries an explicit FDA warning about kidney problems, stating that "kidney problems are common during treatment with ENTRESTO and can be serious and can lead to kidney failure" 1. The drug label mandates that doctors check kidney function during treatment and may need to lower the dose, temporarily stop, or permanently discontinue treatment if renal function deteriorates 1.

Mechanism of Renal Injury

As a consequence of inhibiting the renin-angiotensin-aldosterone system (RAAS), decreases in renal function should be anticipated in susceptible individuals 1. In patients whose renal function depends on RAAS activity (particularly those with severe heart failure), treatment has been associated with oliguria, progressive azotemia, and rarely acute renal failure and death 1.

Real-World Evidence

Recent pharmacovigilance data from the FAERS database demonstrates a significant association between sacubitril/valsartan and acute renal failure, with positive signals detected across multiple statistical algorithms (ROR = 2.37, PRR = 2.34) 2. The analysis revealed that AKI typically occurs within 30 days of initiation, with hospitalization rates of 14-30% for acute renal failure outcomes 2.

In clinical practice studies, AKI was the most common adverse effect, occurring in 14% of hospitalized patients started on sacubitril/valsartan 3. Another study found that 7% of patients required discontinuation specifically due to AKI 4.

Comparative Safety

Importantly, when compared to valsartan alone, sacubitril/valsartan carries a higher renal safety risk based on pharmacovigilance signal analysis 5. However, in older Medicare beneficiaries with heart failure, sacubitril/valsartan was not associated with higher rates of AKI hospitalization compared to traditional renin-angiotensin system inhibitors (HR 0.91,95% CI: 0.72-1.16) 6.

Eplerenone and AKI Risk

Guideline-Based Evidence

The ESC Guidelines explicitly state that eplerenone can cause worsening renal function, which was uncommon in randomized trials but occurs more frequently in ordinary clinical practice, especially in the elderly 7. The guidelines mandate serial monitoring of serum electrolytes and renal function 7.

Specific Monitoring Thresholds

The ESC provides clear cutoffs for action 7:

  • If creatinine rises to >220 μmol/L (2.5 mg/dL): Halve the dose of eplerenone (e.g., to 25 mg on alternate days) and monitor blood chemistry closely
  • If creatinine rises to >310 μmol/L (3.5 mg/dL): Stop eplerenone immediately and monitor blood chemistry closely; specific treatment of renal dysfunction may be needed

Drug Interactions Increasing AKI Risk

NSAIDs combined with eplerenone may cause acute kidney failure by direct impact on glomerular filtration, especially in at-risk patients (elderly and/or dehydrated) 8. Patients receiving eplerenone and NSAIDs need to be well-hydrated, and renal function should be checked before treatment initiation 8.

Cyclosporine and tacrolimus may impair renal function and increase risk when combined with eplerenone; this association should be avoided, or if unavoidable, renal function must be closely monitored 8.

Critical Monitoring Algorithm

For Both Medications:

  1. Before initiation: Check baseline renal function and serum electrolytes 7

  2. Early monitoring:

    • Recheck at 1 and 4 weeks after starting treatment 7
    • For Entresto: Monitor closely as most AKI occurs within first 30 days 2
  3. Ongoing surveillance:

    • At 1,2,3, and 6 months after achieving maintenance dose 7
    • Then every 6 months thereafter 7
  4. High-risk populations requiring intensified monitoring:

    • Elderly patients 7
    • Pre-existing CKD 9
    • Patients on concomitant nephrotoxic drugs (NSAIDs, cyclosporine, tacrolimus) 8
    • Volume-depleted patients 1
    • Bilateral renal artery stenosis 9, 1

Common Pitfalls to Avoid

Do not discontinue these medications for mild or transient reductions in renal function 10. Small to moderate worsening of renal function (defined as ≥20% decrease in eGFR) was not associated with true AKI in heart failure patients on guideline-directed medical therapy 10.

Correct volume or salt depletion prior to administration of Entresto, as volume-depleted patients are at greater risk for both hypotension and renal dysfunction 1.

The "triple whammy" combination (RAAS inhibitor + diuretic + NSAID) substantially increases AKI risk and should be avoided when possible 11. If unavoidable, ensure adequate hydration and close monitoring 8.

Patients with diabetes on these medications have worse safety outcomes and higher 30-day readmission rates, requiring particularly close monitoring 3.

References

Related Questions

Should sacubitril‑valsartan be stopped in a patient with advanced chronic kidney disease who develops acute kidney injury?
What are the common side effects of Entresto (sacubitril/valsartan)?
What is the role of Diuretic use in Acute Tubular Necrosis (ATN)?
Does Entresto (sacubitril/valsartan) worsen Acute Kidney Injury (AKI)?
In a 60‑year‑old patient with recent vomiting, diarrhea, abdominal pain, on lisinopril, who now has acute kidney injury with elevated urine sodium, low urine osmolality, and low urine specific gravity, which diagnosis is most likely: pre‑renal azotemia, acute tubular necrosis, or chronic kidney disease?
What are the dosing and administration recommendations for a low‑potency topical glucocorticoid (hydrocortisone 1% cream) for a patient with advanced liver disease and systemic lupus erythematosus affecting the face?
Do nurse practitioners receive continuing medical education (CME) contact hours for using Dr Oracle?
What are the essential counseling points and management guidelines for patients receiving fruquintinib for metastatic colorectal cancer?
What is the recommended pharmacologic and non‑pharmacologic treatment approach for depression in an elderly patient?
In an 18.5 kg patient with serum calcium 1.457 mmol/L, how do I prepare a calcium gluconate infusion to deliver 10 mg/kg elemental calcium, and over what time should the infusion be administered?
Which of the following are appropriate treatments for viral conjunctivitis: antihistamine/decongestant eye drops, cold compresses, hot compresses, or steroid eye drops?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.